key: cord-0852343-f582sc04
authors: Loganathan, Jemina; Doumouchtsis, Stergios K.
title: Impact of COVID-19 on management of urogynaecology patients: a rapid review of the literature
date: 2021-02-03
journal: Int Urogynecol J
DOI: 10.1007/s00192-021-04704-2
sha: f46647b302b546ace75b7cb363569f295f540c04
doc_id: 852343
cord_uid: f582sc04

INTRODUCTION AND HYPOTHESIS: The coronavirus (COVID-19) pandemic has impacted health systems worldwide. There is a continuing need for clinicians to adapt practice to facilitate timely provision of medical care, whilst minimising horizontal transmission. Guidance and recommendations are increasingly available, and this rapid review aimed to provide a timely evidence synthesis on the current recommendations surrounding urogynaecological care. METHODS: We performed a literature review using PubMed/Medline, Embase and Cochrane and a manual search of national and international societies for management recommendations for urogynaecological patients during the COVID-19 pandemic. RESULTS: Nine guidance documents and 17 articles, including 10 reviews, were included. Virtual clinics are recommended for new and follow-up patients, to assess and initiate treatment, as well as triage patients who require face-to-face appointments. Outpatient investigations such as urodynamics and cystoscopy for benign indications can be deferred. Prolapse and continence surgery should be suspended, except in specific circumstances such as procidentia with upper tract complications and failed pessaries. There is no evidence to support a particular route of surgery, but recommendations are made to minimise COVID-19 transmission. CONCLUSIONS: Urogynaecological patients face particular challenges owing to inherent vulnerabilities of these populations. Behavioural and medical therapies should be recommended as first line options and initiated via virtual or remote clinics, which are integral to management during the COVID-19 pandemic. Expanding the availability and accessibility of technology will be increasingly required. The majority of outpatient and inpatient procedures can be deferred, but the longer-term effects of such practices are unclear. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00192-021-04704-2

Coronavirus (COVID-19) disease caused by the SARS-CoV-2 virus was first declared as a pandemic by the World Health Organization (WHO) on 11 March 2020 [1] . Since then it has continued to rapidly spread worldwide impacting all aspects of life, not least medical care and how clinicians assess and treat patients. Medical providers worldwide have been required to adapt and streamline services to minimise unwarranted, multiple healthcare facility attendances and patient contact where possible, by conducting remote consultations, delaying nonurgent visits and optimising provision of one-stop services.

The urogynaecology scope of practice involves, to a significant proportion, care and management of elderly and vulnerable patients and therefore these measures are of particular importance. As the pandemic continues, national and international societies and organisations have published guidance for management mainly based on consensus and expert advice given that evidence base to support recommendations is still scarce [2] [3] [4] [5] .

Rapid reviews are a method of knowledge or evidence synthesis [6] to produce information in a more timely manner than traditional systematic reviews [7] ; therefore, they are particularly useful for new and emerging topics. Rapid reviews involve an expedited process with omission of certain steps usually performed in a systematic review.

Given the rapid evolution of evidence, recommendations, policies and clinical management adaptations, a rapid review on the current evidence and recommendations is highly warranted. Since the COVID-19 pandemic was declared, several publications have appeared providing narrative reviews in order to bring all the relevant information from the guidelines together in one document, to support patient care [8] [9] [10] . These studies summarise and review published guidelines, original studies, consensus statements, opinions and comments in peerreviewed journals, and professional organisations and societies.

The aim of this rapid review is to systematically review and evaluate the available evidence from published research, as well as to collate guidelines and recommendations in order to provide guidance on the management of urogynaecological conditions and clinical practices in response to the COVID-19 pandemic. This review has been undertaken by CHORUS, An International Collaboration for Harmonising Outcomes, Research and Standards in Urogynaecology and Women's Health (i-chorus.org).

We performed a literature review using the OvidSP search platform and interrogating through this the databases PubMed/Medline, Embase and Cochrane using keywords and MeSH terms including: COVID-19, SARS-CoV-2, coronavirus, incontinence, pelvic organ prolapse, vaginal prolapse, uterine prolapse, cystocele, rectocele, bladder pain, childbirth trauma, perineal trauma, perineal laceration, urogynaecology, urogynecology, overactive bladder (OAB), recurrent cystitis, recurrent urinary tract infections (UTIs); (Appendix 1).

Literature searches were conducted from 1 January to 22 September 2020. We searched the references of the relevant studies manually using the backward snowballing method [11] in order to identify additional eligible references and studies. In addition, a manual search was conducted of national and international specialist societies and organisations in order to identify practice guidance. We searched the websites of the International Urogynecological Association (IUGA), International Continence Society (ICS), European Association of Urology (EAU), British Society of Urogynaecology (BSUG), Royal College of Obstetricians and Gynaecologists (RCOG), Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), American Urological Association (AUA), American Urogynecologic Society (AUGS), Asia-Pacific Urogynecology Association (APUGA), Urogynecologist Asia (UG-Asia), Urological Association of Asia (UAA), South African Urogynaecological Association (SAUGA) and Pan African Urological Association (PAUSA). The latest version of guidelines was used in cases where more than one guideline or update was available. The final decision about the inclusion of guidelines and published articles was based on authors' consensus.

All searches were restricted to English-language publications or those with the facility to translate to English, guidelines and best-practice statements. We did not exclude original articles, comments or perspectives. Inclusion criteria were the presence in the articles of guidance or practical advice for the management of urogynaecology patients during the COVID-19 pandemic.

Exclusion criteria were non-English-language articles with translation not readily available, guidelines unavailable to the public in full text, not involving urogynaecology care or not involving urogynaecology care during the COVID-19 pandemic.

Study selection was conducted in stages. Following title screening, the abstracts of all articles in the database were examined. Two reviewers scrutinised the full text of each article and evaluated the studies potentially eligible for inclusion against the inclusion criteria. Discrepancies regarding inclusion or exclusion were resolved through discussion.

Ethical approval was not required for this review. One reviewer extracted relevant data from all eligible articles. The content of each guideline or article was tabulated including the title of the guidance or article, issuing association or journal, and date of publication.

The quality of guidelines was evaluated using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument [12] and the quality of reviews assessed using Scale for the Assessment of Narrative Review Articles (SANRA) [13] .

Nine guidance documents and 17 articles, 10 of which are reviews, were included ( Fig. 1 ; Table 1 ).

Quality assessment of guidelines was performed using Appraisal of Guidelines for Research and Evaluation II instrument (AGREEII). Overall assessment scores are shown in Table 1 (1 lowest quality to 7 highest quality). See Appendix 2 for individual domain scores.

Review articles were assessed using the Scale for the Assessment of Narrative Review Articles (SANRA) with a maximum score of 12. See Appendix 3 for the full SANRA scale.

All 12 articles and guidelines that included outpatient clinic recommendations stated that virtual clinics should be used to minimise horizontal transmission. Virtual clinics can be used for all non-urgent indications such as urinary incontinence and prolapse, and for both initial consultations and follow-up appointments. Patient satisfaction is unaffected and clinic attendance may be increased owing to a reduction in non-attendance [19] .

When used for postoperative follow-up there is no increase in adverse outcomes [19] . For patients awaiting surgery, virtual clinics can be conducted to rediscuss alternative therapies.

During virtual clinics, patients can be triaged and limited face-to-face appointments arranged if necessary. When seen face to face, appropriate screening should be undertaken, personal protective equipment (PPE) worn, physical distance maintained, and sanitation available [31] .

It has been reported that COVID-19 transmission could be as high as 12.8% at a physical distance of less than 1 m compared with 2.6% at a distance of more than 1 m, reflecting the importance of maintaining physical distance [34] .

In keeping with these findings, the Scientific Advisory Group for Emergencies (SAGE), who provide scientific and technical advice to support government decision makers in the UK, reported that COVID-19 transmission could be 2-10 times higher at a physical distance of 1 m compared with 2 m [35] . See Table 2 for a summary of guidance for virtual clinics and inpatient admissions. [17] Postoperative follow-up can be virtual Non-inferior for patient satisfaction, complication rates and adverse events [31] Cancel all face-to-face outpatient appointments Virtual consultations where possible Can identify patients requiring urgent consultation [28] Initial and follow-up consultations can be virtual If seeing face-to-face, patient to wear surgical mask and gloves, clinician to wear apron, surgical mask, visor and gloves Triage patients for face-to-face consultation Invasive tests: clinician wears N95 mask, impermeable gown, gloves and visor [19] Virtual clinics: patient satisfaction unaffected, can increase clinic attendance Postoperative virtual clinics: no increase in adverse outcomes or primary care visits Native tissue prolapse repair and mid-urethral sling with no incontinence can be safely followed up in virtual clinic Triage all patients for virtual clinic: established patients not requiring examination, new patients who would benefit from non-surgical treatment, postponed patients awaiting surgery to rediscuss alternative therapies Provide patient information leaflets from established bodies [8] Virtual clinics Physical distancing Sanitisation areas Work from home Limit friends and family accompanying Minimise face-to-face Adequate PPE [3] Virtual clinic for pessary follow-up Triage patients: see semi-urgently, within 30 days or delayed review [16] U s et e l e m e d i c i n e Avoid face-to-face where possible [26] Telemedicine to minimise exposure [22] U s et e l e m e d i c i n e Avoid face-to-face where possible Use telemedicine to assess need for face-to-face review Postoperative follow-up: equal patient-related outcomes with telemedicine compared with face-to-face [36] Use video or teleconsults for all non-urgent indications [5] Use telemedicine to allow physical distancing and minimise footfall [18] Telemedicine whilst awaiting surgery to help with symptom management [15] Essential staff only in clinic rooms Discourage accompanying persons Physical distancing Cleaning surfaces with appropriate disinfectant Handwashing before and after patient contact Waiting and clinic room with appropriate safe spacing COVID-19 positive or those in isolation should not be seen face-to-face. If no option, then wear appropriate PPE If face-to-face appointment, screen all patients and accompanying persons for symptoms, travel and exposure PPE personal protective equipment Of 15 articles and guidelines providing recommendations regarding the management of urinary incontinence and OAB, 12 advise behavioural therapies as the first line.

Two recommend use of smart phone apps to supplement education, for example, for Kegel exercises [19, 26] . Suspension of invasive therapies for urinary incontinence is advised, except where stage 1 sacral neuromodulation is in place or in cases of neurogenic bladder with a high risk of upper renal tract complications [33] . Pelvic floor muscle training is recommended as the first-line for symptomatic prolapse [16, 17, 19, 23, 26] ; however, in one editorial, suspension of pelvic floor muscle training is suggested to maintain physical distancing [36] .

Use of pessaries is recommended, whilst prolapse surgery is deferred [16, 26, 36] , and the pessary change interval can be extended by 3-6 months unless the patient has symptoms of ulceration or fistulation [3, 24, 27] . See Table 3 for a summary of guidance for urinary incontinence and prolapse.

Acute retention or a blocked catheter warrants urgent review for catheterisation [20] .

If an indwelling catheter is in situ, routine changes can be deferred for 2-4 weeks, unless the patient has a history of difficult changes or recurrent UTIs [24] . Deferring suprapubic catheter changes [3, 20] for up to 3 months has been suggested and changes in the community rather than in the hospital setting are preferred [3, 36] .

Urinary tract infections can be managed via virtual consultation [17, 19, 23, 25] . If the patient has recurrent UTIs conservative measures and non-antibiotic therapies should be encouraged [17] . If antibiotics are required, they should be prescribed according to previous culture results. Face-to-face review should be arranged if the patient has complicated UTI or is refractory to treatment [19] . See Table 4 for a summary of voiding dysfunction and urinary tract infection.

Gross haematuria requires urgent investigation with cystoscopy; however, microscopic haematuria investigations can be deferred. A systematic review of telemedicine in urology, however, reported that data indicate that virtual clinics for initial evaluation are feasible, effective, and associated with a high degree of patient satisfaction [23] .

Bladder pain syndrome investigations should be deferred, but oral treatments can be started [5, 28] .

Fourteen articles reported recommendations for outpatient procedures, including cystoscopy, intravesical Botox and Use non-surgical management UI as advised by IUGA [23] Evidence that behavioural measures and PFMT via video conferencing as effective as face-to-face Use of behavioural measures and PFMT [5] Use conservative and medical treatments [24] Can delay pessary change up to 3 months if no erosion or ulcer [20] Acute retention: see face-to-face Defer all SPC and IDC changes [14] Acute retention: see face-to-face for IDC or SPC [3] If acute retention need emergency/urgent review (within 12 hours) for IDC If arranging TWOC, can defer on a case-by-case basis. If high PVR, then teach CISC Change of SPC can be delayed up to 3 months Aim for SPC change in community not hospital setting [25] Encourage conservative measures to help void, e.g. double/triple voiding Empirical treatment of UTI, including recurrent UTI Chronic urinary retention, e.g. >300 ml for >6 months, consider USS KUB and face-to-face consultation for ISC or IDC Electronic prescribing is effective and efficient ISC preferable to IDC Resolution of symptoms indicative of cure Teach ISC face-to-face, follow-up via virtual clinic [36] Acute retention: place IDC or SPC, change regularly in the community. Consider ISC if teaching and education possible [30] Obstructive urinary disorders-face-to-face clinics with reduced capacity [5] Voiding dysfunction: teach ISC or catheterise Sepsis/complicated UTI: high priority Blocked catheter requires emergency review [23] Can be managed safely and effectively using telemedicine BSUG British Society of Urogynaecology, EAU European Association of Urology, PVR post-void residual volume, ISC intermittent self-catheterisation, IDC indwelling urethral catheter, SPC suprapubic catheter, US KUB ultrasound of the kidneys, ureters and bladder, UTI urinary tract infection, CISC clean intermittent self-catheterisation, TWOC trial without catheter [17] Referral to secondary care if gross haematuria [24] Gross haematuria: urgent cystoscopy, no deferring Delay urodynamics for 3-6 months Microscopic haematuria with risk factors: can defer for up to 3 months unless symptomatic Microscopic haematuria and no symptoms: can defer for 3 months or more [27] Most but not all experts recommend urgent cystoscopy for macroscopic haematuria. EAU and USANZ say it can be deferred for 1-2 months Delay urodynamics. Time frame 1-6 months Neurogenic intravesical Botox can be deferred for up to 4 weeks Slings: clinical harm unlikely if postponed for 6 months [20] Macroscopic haematuria: urgent cystoscopy Defer all cystoscopy for benign conditions Microscopic: postpone [23] Use telemedicine for initial haematuria consult and triage, then see face-to-face if needed [30] Continue cystoscopy for suspected cancer All outpatient cystoscopy suspended, continue only for suspected cancer [28] Delay BPS investigations until after COVID Do not commence new intravesical Botox treatments Use oral medications, e.g. amitriptyline Delay intravesical Botox until end of COVID crisis Continue bladder instillation if self-administered already Defer if administered in hospital [19] Consider face-to-face review if acute BPS flare requiring instillation [5] Manage BPS conservatively All urodynamics postponed Can offer amitriptyline [31] All urodynamics postponed Intravesical Botox can be carried out under local anaesthetic for high-risk patients, e.g. autonomic dysreflexia [14] Defer all cystoscopy for benign conditions [3] Defer all outpatient treatments and investigations, i.e. cystoscopy (non-cancer indications), bladder instillations, PTNS [16] Intravesical Botox suspended unless neurological bladder with upper tract risk Cystoscopy: perform within 2 months if risk factors for cancer and refractory OAB [25] If planned intravesical Botox, can defer and restart antimuscarinics/B3 agonists [36] Intravesical Botox postponed. Consider continuing under local anaesthesia for neurogenic bladder with renal tract complications [29] Intravesical Botox: non-essential, i.e., not time sensitive unless, e.g. failure of conservative and progressive symptoms [18] Tier Aim for local/regional anaesthetic if possible Negative pressure in theatre High frequency of filtered air exchange Essential theatre staff only Most experienced surgeon operating PPE when GA: water repellent, long-sleeved gowns, eye and face protection, gloves and FFP3 respirators If pyrexial within 30 days screen and retest for COVID-19 [28] No contraindications to open, transurethral and vaginal procedures Low power setting for electrosurgery Special care to be taken with laparoscopic and robotic procedures Avoid long desiccation times

Consider local anaesthesia where possible to minimise AGPs Closed smoke evacuation/filtration system with ULPA capability COVID testing for any at-risk patient prior to surgery according to local guidelines and availability

Laparoscopic suction to remove smoke and deflate abdomen

Most surgery is priority level 4 and can be deferred over 3 months Low intra-abdominal pressure 10-12 mmHg if feasible Avoid rapid deflation Minimise blood/fluid droplet spread Be careful at time of instrument exchange and tissue extraction Minimise CO 2 leakage from trocars [27] Endoscopic and robotic surgery: low electrocautery settings to generate less smoke, lowest pressure insufflation, only essential staff present in theatre, all staff in PPE [20] Route of surgery at surgeon's discretion Use closed system for insufflation Smoke extractor Adequate PPE Use lowest intrabdominal pressure possible Use lowest cautery setting possible [8] Symptom screen and COVID test all patients preoperatively Shorter hospital stay Clean COVID-free sites for surgery Can physical distance more than in open surgery All elective surgery for benign indications suspended Risk of COVID transmission if not operating on GI tract during laparoscopy is low Low power diathermy. Closed smoke evacuation Filtration system Use suction to deflate abdomen Low pressure 10-12 mmHg intraoperatively Avoid rapid desufflation, minimise blood or fluid spray Check seals around all reusable ports GA in negative pressure room [14] Experienced surgeon to minimise operating time Filter system to reduce viral release with gas Clinical trials and trials of new technology to be postponed Low pressure pneumoperitoneum COVID test all patients preoperatively Low bipolar cautery setting Temperature testing and wearing masks on arrival Reduce inpatient beds to allow physical distancing [4] Suspend all elective surgery Low intra-abdominal pressure 10-12 mmHg Universal COVID-19 testing recommended before all surgery Low power settings for electrosurgical devices [30] Only urgent procedures to minimise inpatient stays Safety of minimally invasive surgery remains undetermined Screening consultation prior to procedure-symptoms in last 2 weeks, any travel Test patients and clinical team prior to procedure Positive pressure on hold during procedure and restarted 20 min after patient leaves Limited personnel in theatre [5] Recommend only high priority/emergency cases, experienced surgeon

Minimal staff numbers, no observers Suction of gas prior to removing ports Intubation and extubation in negative pressure room

Smoke evacuation system capable of filtering aerosolized particles from CO 2 should be provided for laparoscopic surgery Use low cautery settings [31] All invasive procedures under GA deferred [19] All elective cases deferred Aim for same-day discharge where possible Spinal anaesthesia in preference to general anaesthesia, unlikely to greatly increase voiding dysfunction [25] Transmission of fomites during vaginal surgery appears highly unlikely Regional anaesthesia preferable to general anaesthesia-lower risk postoperative retention, reduces aerosol generation [36] Augmentation cystoplasty, cystectomy, and continent and incontinent diversions all postponed owing to high-dependency in-patient care required urodynamics. All urodynamics and cystoscopy for benign indications should be deferred. See Table 5 for a summary of guidance for haematuria, bladder pain syndrome and outpatient procedures.

Recommendations regarding surgery advise regional or local anaesthesia where possible, in order to reduce aerosol generation with general anaesthesia [2, 19, 25, 28] . Screening for COVID-19 symptoms and testing preoperatively is advised, as evidence has shown poorer surgical outcomes for asymptomatic COVID-19 patients, therefore surgery may worsen or accelerate progression [2, 4, 5, 8, 14, 21, 28, 30] Although better able to maintain physical distance and potentially shorter hospital stays with laparoscopic surgery than with open surgery [8] , no evidence is available to support a specific route of surgery; therefore, this is at the surgeon's discretion [5, 20] .

Recommendations to reduce horizontal transmission in surgery include having essential staff only in theatre, low electrocautery settings, closed smoke evacuation and minimising blood and fluid droplet spray [4, 5, 8, 14, 16, 20, 27, 28] . See Table 6 for a summary of guidance for elective surgery and techniques to minimise horizontal transmission.

Continuing or restarting surgery during the pandemic requires prioritisation of cases, taking into account the severity of the pathology, patient comorbidities and the impact on physical and mental health and quality of life. Seven documents specified prioritisation guidance. See Table 7 for a summary of the prioritisation of surgery.

We followed a standardised rapid review methodology in order to provide a summary of recommendations and practice guidelines in a timely manner. We performed a comprehensive literature search including published articles, articles in press and association guidelines to ensure that we identified and included all available evidence regarding management of urogynaecology patients during the COVID-19 pandemic.

There is a high degree of consensus regarding the use of virtual clinics, management outpatient procedures, and surgical techniques to minimise horizontal transmission of COVID-19.

However, variations in recommendations exist and are summarised in this review. Therefore, it can be used as a resource to support adjustments in practice as local conditions evolve.

As further evidence emerges, resources change and the pandemic continues, this synthesis of available guidance can be used as a reference for clinicians to guide management.

Given the aim to issue a summary without delay using rapid review methodology, some studies may have been omitted, which is an inherent limitation of rapid reviews. There is susceptibility to bias in streamlining a systematic review process, for example, in choosing studies for inclusion or exclusion and in data extraction, as fewer independent reviewers conduct each step.

Recommendations are predominantly based on expert opinion and, given the rapidly evolving nature of the COVID-19 virus, there is often a lack of robust scientific evidence [8] for clinically relevant questions.

Indeed, the COVID-19 "infodemic" has been described by WHO as an "overabundance of information-some accurate and some not-that occurs during an epidemic" [37] . [16] A: continue, e.g. second-stage neuromodulation, intravesical Botox for neurogenic bladder with risk of high bladder pressure, surgery for grade 4 prolapse with acute renal failure and failed pessary B: 1-8 weeks, e.g. refractory OAB and bladder cancer risk factors C: delay 8-16 weeks, e.g. intravesical Botox D: can be delayed >16 weeks, e.g. stress urinary incontinence surgery [29] 1: urgent, <1 month-delay could cause major harm, e.g. prolapse beyond hymen with voiding dysfunction or upper renal tract complications 2: essential elective, <3 months-increased risk of adverse outcomes if delayed for undetermined time period, e.g. prolapse beyond hymen with progressive symptoms, impaired QoL, failed pessaries but no upper renal tract complications 3: non-essential elective, postpone up to 1 year-not time sensitive, e.g. prolapse beyond hymen with no upper renal tract complications and able to use pessary Continence surgery: non-essential elective, unless failure of conservative and progressive symptoms [21] Category 1: urgent: within 30 days, potential to deteriorate and become an emergency Category 2: semi-urgent: within 60 days, causes pain dysfunction or disability, but unlikely to deteriorate quickly, unlikely to become an emergency Category 3: elective: within 365 days, causes pain dysfunction or disability, unlikely to deteriorate quickly, does not have potential to become emergency All urogynaecology cases are category 3, should be postponed. Can start in highly symptomatic patients when risk of transmission reduces, depending on local situations [5] Low priority: clinical harm very unlikely if postponed for 6 months, e.g. stress or urge incontinence surgery, surgery for urethral diverticula Intermediate: clinical harm possible if postponed for 3-4 months but unlikely, e.g. surgical management of patients with urinary retention, intravesical Botox for selected cases of neurogenic bladder High priority: clinical harm likely if postponed for over 6 weeks, e.g. cystoscopy for macroscopic haematuria Emergency: life-threatening situation and likely to have presented in ED despite pandemic [18] Tier 1: non-life-threatening illness, low acuity, i.e. SUI surgery, laparoscopic sacrocolpopexy, native tissue transvaginal prolapse surgery, asymptomatic mesh exposure Tier 2: non-life-threatening, but potential for near future morbidity or mortality, intermediate acuity, i.e. fistula repair, mesh-related complication, e.g. severe pain/infection Tier 3: high potential for near future morbidity or mortality, severe impairment of QoL, high acuity, i.e. prolapse with upper tract obstruction and unable to retain pessary, obstructed voiding after MUS Tier 4: emergency surgery Each tier has subsets A and B Subset B denotes patients with comorbidities that may be deferred until after lower acuity patients EAU European Association of Urology, BPS bladder pain syndrome, OAB overactive bladder, SUI stress urinary incontinence, ED emergency department, MUS mid-urethral sling, QoL Quality of life This is an inherent limitation of all reviews in this area given the unprecedented public health crisis and the epidemiological characteristics of the current pandemic.

As the COVID-19 pandemic continues, and our understanding and resources change, there is high potential for modifications within recommendations and publication of further guidance, which may have already occurred during publication of this rapid review.

The COVID-19 pandemic has changed the way in which we conduct healthcare and will do so for the foreseeable future. Evidence suggests that a large proportion of urogynaecological conditions might be able to be managed using virtual consultations utilising behavioural measures, lifestyle changes and medical therapy. Outpatient procedures in one-stop clinics to investigate and treat conditions such as refractory OAB can be maximised to avoid inpatient admissions, and to reduce the frequency of visits and the use of general anaesthesia.

Technology is required to maintain and develop the quality of virtual consultations and this is particularly important for remote teaching of clean intermittent self-catheterisation, home trial without catheter, pessary management and triaging symptoms. For those unable to use or without access to the required technology, smaller ad hoc face-to-face clinics with PPE and physical distancing should be considered.

Various healthcare providers and organisations have developed and published guidance for practice, which should always be observed, as it is linked and adapted to local policies, sociodemographic and epidemiological conditions, as well as infrastructures. This review is aimed at providing a wider perspective on practice recommendations that have been published to date and can be adapted or even considered for implementation at local levels.

Although adaptations and provisions are being made to manage urogynaecological conditions, given that the majority of patients are elderly with comorbidities that increase risk of COVID-19 morbidity and mortality, and with most surgical procedures for quality of life, the resumption of elective activity is expected to be slow. Consequently, there is likely to be a significant impact on quality of life within this cohort of patients and the impact of delayed diagnosis and treatment on the trajectory of the disease is yet to be determined.

The online version contains supplementary material available at https://doi.org/10.1007/s00192-021-04704-2

Funding S.D. has previously had expenses paid by Contura. There are no funding disclosures for this review article.

Conflicts of interest The authors declare that they have no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

World Health Organisation Virtual press conference on COVID-19

Joint RCOG/BSGE Statement on gynaecological endoscopy during the COVID-19 pandemic

BSUG guidance on management of urogynaecological conditions and vaginal pessary use during the Covid 19 pandemic

Joint statement on minimally invasive gynecologic surgery during the COVID-19 pandemic-general-news | AUGS

European Association of Urology Guidelines Office Rapid Reaction Group: an organisation-wide collaborative effort to adapt the EAU guidelines recommendations to the COVID-19 era

Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews

A scoping review of rapid review methods

COVID-19 and gynecological cancer: a review of the published guidelines

Covid-19: what is the best approach in gynecological oncology patient management during the coronavirus pandemic?

COVID-19 and laparoscopic surgery: scoping review of current literature and local expertise

Guidelines for snowballing in systematic literature studies and a replication in software engineering

AGREE II: Advancing guideline development, reporting and evaluation in health care

SANRA-a scale for the quality assessment of narrative review articles

Urology practice during the COViD-19 pandemic

COVID-19: outpatient services; office consultations and procedures

French Association of Urology. COVID-19: recommendations for functional urology

Guidance for the management of urogynecological conditions during the coronavirus (COVID-19) pandemic iuga

Joint statement on reintroduction of hospital and office-based procedures in the COVID-19 climate for the practicing urogynecologist and gynecologist

A guide for urogynecologic patient care utilizing telemedicine during the COVID-19 pandemic: review of existing evidence

Forecasting the future of urology practice: a comprehensive review of the recommendations by international and European associations on priority procedures during the COVID-19 pandemic

Practical recommendations for gynecologic surgery during the COVID-19 pandemic

Guidance for gynecologists utilizing telemedicine during COVID-19 pandemic based on expert consensus and rapid literature reviews

Telehealth in urology: a systematic review of the literature. How much can telemedicine be useful during and after the COVID-19 pandemic?

Triaging office based urology procedures during the COVID-19 pandemic

How did COVID-19 pandemic change the way we attend the patients in an urogynaecological unit

A lasting impression: telemedicine in urogynecology during the coronavirus disease 2019 pandemic

A systematic review on guidelines and recommendations for urology standard of care during the COVID-19 pandemic

Management of female and functional urology patients during the COVID pandemic

Resumption of elective surgery following COVID-19 outbreak, guideline for female pelvic medicine and surgery

Global challenges to urology practice during the COVID-19 pandemic

Technology-based management of neurourology patients in the COVID-19 pandemic: is this the future? A report from the International Continence Society (ICS) institute

Virtual consent for virtual patients: benefits of implementation in a peri-and post-COVID-19 era

Neuro-urology during the COVID-19 pandemic: triage and priority of treatments

Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis

Transmission of SARS-CoV-2 and mitigating measures. EMG-SAGE

Widespread postponement of functional urology cases during the COVID-19 pandemic: rationale, potential pitfalls, and future consequences

COVID-19: the deadly threat of misinformation

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations